These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 25270293)

  • 41. Hematopoietic, immunomodulatory and epithelial effects of interleukin-11.
    Schwertschlag US; Trepicchio WL; Dykstra KH; Keith JC; Turner KJ; Dorner AJ
    Leukemia; 1999 Sep; 13(9):1307-15. PubMed ID: 10482979
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Detection and quantification of transforming growth factor beta (TGF-beta) and platelet-derived growth factor (PDGF) release by normal human megakaryocytes.
    Wickenhauser C; Hillienhof A; Jungheim K; Lorenzen J; Ruskowski H; Hansmann ML; Thiele J; Fischer R
    Leukemia; 1995 Feb; 9(2):310-5. PubMed ID: 7869769
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Growth factors of the future.
    Nemunaitis J
    Leuk Lymphoma; 1993 Mar; 9(4-5):329-36. PubMed ID: 8348068
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Suppression of lymphokine-activated killer (LAK) cell induction mediated by interleukin-4 and transforming growth factor-beta 1: effect of addition of exogenous tumour necrosis factor-alpha and interferon-gamma, and measurement of their endogenous production.
    Brooks B; Chapman K; Lawry J; Meager A; Rees RC
    Clin Exp Immunol; 1990 Dec; 82(3):583-9. PubMed ID: 2124961
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recombinant human IL-11 attenuates the inflammatory response through down-regulation of proinflammatory cytokine release and nitric oxide production.
    Trepicchio WL; Bozza M; Pedneault G; Dorner AJ
    J Immunol; 1996 Oct; 157(8):3627-34. PubMed ID: 8871663
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cytokine-mediated induction of cyclo-oxygenase-2 by activation of tyrosine kinase in bovine endothelial cells stimulated by bacterial lipopolysaccharide.
    Akarasereenont P; Bakhle YS; Thiemermann C; Vane JR
    Br J Pharmacol; 1995 Jun; 115(3):401-8. PubMed ID: 7582449
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Real-world safety experience of tevagrastim/ratiograstim/biograstim and tbo-filgrastim, short-acting recombinant human granulocyte colony-stimulating factors.
    Abboud CN; Lang N; Fung H; Lammerich A; Buchner A; Liu P; Mueller U; Pettengell R; Diel IJ; Link H; Pathak A
    Support Care Cancer; 2019 Jul; 27(7):2569-2577. PubMed ID: 30443809
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of various recombinant human hemopoietic growth factors (rhEpo, rhG-CSF, rhGM-CSF, rhIl-3) on the growth of peripheral blood progenitor cells (BFU-E, CFU-GM).
    Serke S; Huhn D
    Blut; 1990 Jul; 61(1):25-9. PubMed ID: 1696841
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of granulocyte-macrophage colony-stimulating factor and interleukin-3 on interleukin-8 production by human neutrophils and monocytes.
    Takahashi GW; Andrews DF; Lilly MB; Singer JW; Alderson MR
    Blood; 1993 Jan; 81(2):357-64. PubMed ID: 7678512
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Platelet-derived growth factor (PDGF) in human acute myelogenous leukemia: PDGF receptor expression, endogenous PDGF release and responsiveness to exogenous PDGF isoforms by in vitro cultured acute myelogenous leukemia blasts.
    Foss B; Ulvestad E; Bruserud Ø
    Eur J Haematol; 2001 Oct; 67(4):267-78. PubMed ID: 11860452
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Twenty-five years of recombinant human growth factors rhPDGF-BB and rhBMP-2 in oral hard and soft tissue regeneration.
    Galarraga-Vinueza ME; Barootchi S; Nevins ML; Nevins M; Miron RJ; Tavelli L
    Periodontol 2000; 2024 Feb; 94(1):483-509. PubMed ID: 37681552
    [TBL] [Abstract][Full Text] [Related]  

  • 52. c-jun expression and growth stimulation in human ovarian carcinoma cell lines following exposure to cytokines.
    Spinner DM; Brandstetter T; Kiechle-Schwarz M; Du Bois A; Angel P; Bauknecht T
    Int J Cancer; 1995 Nov; 63(3):423-7. PubMed ID: 7591243
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Additive effects of human recombinant interleukin-11 and granulocyte colony-stimulating factor in experimental gram-negative sepsis.
    Opal SM; Jhung JW; Keith JC; Goldman SJ; Palardy JE; Parejo NA
    Blood; 1999 May; 93(10):3467-72. PubMed ID: 10233899
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reduced secondary cytokine induction by BAY 50-4798, a high-affinity receptor-specific interleukin-2 analog.
    Steppan S; Eckart MR; Bajsarowicz K; Sternberg LR; Greve JM; Cassell DJ
    J Interferon Cytokine Res; 2006 Mar; 26(3):171-8. PubMed ID: 16542139
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New cytokine dressings. I. Kinetics of the in vitro rhG-CSF, rhGM-CSF, and rhEGF release from the dressings.
    Grzybowski J; Ołdak E; Antos-Bielska M; Janiak MK; Pojda Z
    Int J Pharm; 1999 Jul; 184(2):173-8. PubMed ID: 10387946
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biologics as countermeasures for acute radiation syndrome: where are we now?
    Singh VK; Romaine PL; Newman VL
    Expert Opin Biol Ther; 2015 Apr; 15(4):465-71. PubMed ID: 25416452
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tolerability and side-effect profile of rhIL-11.
    Smith JW
    Oncology (Williston Park); 2000 Sep; 14(9 Suppl 8):41-7. PubMed ID: 11033837
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34(+) cells and their transmigration through reconstituted basement membrane.
    Janowska-Wieczorek A; Marquez LA; Nabholtz JM; Cabuhat ML; Montaño J; Chang H; Rozmus J; Russell JA; Edwards DR; Turner AR
    Blood; 1999 May; 93(10):3379-90. PubMed ID: 10233890
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Significance of donors treatment with combination of recombinant human interleukin-11 and recombinant human granulocyte-colony stimulating factor in reduction of incidence of lethal grafts versus host disease after allogeneic bone marrow transplantation].
    Zhao J; Zhao XY; Huang XJ
    Zhonghua Yi Xue Za Zhi; 2005 Sep; 85(35):2497-502. PubMed ID: 16321278
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sequential administration of recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a phase I/II multicenter study.
    Fay JW; Lazarus H; Herzig R; Saez R; Stevens DA; Collins RH; Piñeiro LA; Cooper BW; DiCesare J; Campion M
    Blood; 1994 Oct; 84(7):2151-7. PubMed ID: 7919329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.